KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Income: 2011-2025

Historic Net Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Net Income fell 217.20% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 131.95%. This contributed to the annual value of $73.9 million for FY2024, which is 5512.84% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Net Income of -$45.1 million as of Q3 2025, which was down 300.53% from $22.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Net Income's 5-year high stood at $38.5 million during Q3 2024, with a 5-year trough of -$45.1 million in Q3 2025.
  • Moreover, its 3-year median value for Net Income was $1.2 million (2023), whereas its average is $3.7 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Net Income soared by 2,506.53% in 2024, and later slumped by 9,641.13% in 2025.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Net Income stood at $2.4 million in 2021, then soared by 943.45% to $25.5 million in 2022, then crashed by 95.39% to $1.2 million in 2023, then soared by 1,208.68% to $15.4 million in 2024, then tumbled by 217.20% to -$45.1 million in 2025.
  • Its Net Income was -$45.1 million in Q3 2025, compared to $22.5 million in Q2 2025 and -$11.8 million in Q1 2025.